1
|
Tramper‐Stranders G, Ambrożej D, Arcolaci A, Atanaskovic‐Markovic M, Boccabella C, Bonini M, Karavelia A, Mingomataj E, O' Mahony L, Sokolowska M, Untersmayr E, Feleszko W. Dangerous liaisons: Bacteria, antimicrobial therapies, and allergic diseases. Allergy 2021; 76:3276-3291. [PMID: 34390006 DOI: 10.1111/all.15046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Accepted: 07/31/2021] [Indexed: 12/15/2022]
Abstract
Microbiota composition and associated metabolic activities are essential for the education and development of a healthy immune system. Microbial dysbiosis, caused by risk factors such as diet, birth mode, or early infant antimicrobial therapy, is associated with the inception of allergic diseases. In turn, allergic diseases increase the risk for irrational use of antimicrobial therapy. Microbial therapies, such as probiotics, have been studied in the prevention and treatment of allergic diseases, but evidence remains limited due to studies with high heterogeneity, strain-dependent effectiveness, and variable outcome measures. In this review, we sketch the relation of microbiota with allergic diseases, the overuse and rationale for the use of antimicrobial agents in allergic diseases, and current knowledge concerning the use of bacterial products in allergic diseases. We urgently recommend 1) limiting antibiotic therapy in pregnancy and early childhood as a method contributing to the reduction of the allergy epidemic in children and 2) restricting antibiotic therapy in exacerbations and chronic treatment of allergic diseases, mainly concerning asthma and atopic dermatitis. Future research should be aimed at antibiotic stewardship implementation strategies and biomarker-guided therapy, discerning those patients that might benefit from antibiotic therapy.
Collapse
Affiliation(s)
- Gerdien Tramper‐Stranders
- Department of Pediatrics Franciscus Gasthuis & Vlietland Rotterdam the Netherlands
- Department of Neonatology Erasmus Medical CenterSophia Children's Hospital Rotterdam the Netherlands
| | - Dominika Ambrożej
- Department of Pediatric Pneumonology and Allergy Medical University of Warsaw Warsaw Poland
- Doctoral School Medical University of Warsaw Warsaw Poland
| | - Alessandra Arcolaci
- Immunology Unit University of Verona and General Hospital Borgo Roma Hospital Verona Italy
| | | | - Cristina Boccabella
- Department of Cardiovascular and Thoracic Sciences Università Cattolica del Sacro CuoreFondazione Policlinico Universitario A. Gemelli – IRCCS Rome Italy
| | - Matteo Bonini
- Department of Cardiovascular and Thoracic Sciences Università Cattolica del Sacro CuoreFondazione Policlinico Universitario A. Gemelli – IRCCS Rome Italy
- National Heart and Lung Institute (NHLI) Imperial College London London UK
| | - Aspasia Karavelia
- Department of Ear‐Nose‐Throat surgery General Hospital of Kozani Kozani Greece
| | - Ervin Mingomataj
- Department of Allergology & Clinical Immunology ‘Mother Theresa’ School of Medicine Tirana Albania
| | - Liam O' Mahony
- Departments of Medicine and Microbiology APC Microbiome IrelandNational University of Ireland Cork Ireland
| | - Milena Sokolowska
- Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Zurich Switzerland
| | - Eva Untersmayr
- Institute of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Wojciech Feleszko
- Department of Pediatric Pneumonology and Allergy Medical University of Warsaw Warsaw Poland
| | | |
Collapse
|
2
|
Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilò MB, Akdis CA, Antolín-Amérigo D, Cichocka-Jarosz E, Gawlik R, Jakob T, Kosnik M, Lange J, Mingomataj E, Mitsias DI, Ollert M, Oude Elberink JNG, Pfaar O, Pitsios C, Pravettoni V, Ruëff F, Sin BA, Agache I, Angier E, Arasi S, Calderón MA, Fernandez-Rivas M, Halken S, Jutel M, Lau S, Pajno GB, van Ree R, Ryan D, Spranger O, van Wijk RG, Dhami S, Zaman H, Sheikh A, Muraro A. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018; 73:744-764. [PMID: 28748641 DOI: 10.1111/all.13262] [Citation(s) in RCA: 236] [Impact Index Per Article: 39.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/21/2017] [Indexed: 01/27/2023]
Abstract
Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic-allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate to severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1 -antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence-based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta-analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom-allergic children and adults to prevent further moderate-to-severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline autoinjector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence.
Collapse
|
3
|
Dhami S, Nurmatov U, Varga EM, Sturm G, Muraro A, Akdis CA, Antolín-Amérigo D, Bilò MB, Bokanovic D, Calderon MA, Cichocka-Jarosz E, Elberink JNGO, Gawlik R, Jakob T, Kosnik M, Lange J, Mingomataj E, Mitsias DI, Mosbech H, Pfaar O, Pitsios C, Pravettoni V, Roberts G, Ruëff F, Sin BA, Sheikh A. Erratum to: Allergen immunotherapy for insect venom allergy: protocol for a systematic review. Clin Transl Allergy 2017; 7:30. [PMID: 28932384 PMCID: PMC5602940 DOI: 10.1186/s13601-017-0165-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 08/24/2017] [Indexed: 11/10/2022] Open
Affiliation(s)
| | - Ulugbek Nurmatov
- Systematic Review at Decision Resources Group, Abacus International, Bicester, UK
| | - Eva-Maria Varga
- Respiratory and Allergic Disease Division, Department of Pediatric and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - Gunter Sturm
- Department of Dermatology and Venerology, Medical University of Graz and Outpatient Allergy Clinic Reumannplatz, Vienna, Austria
| | - Antonella Muraro
- Department of Women and Child Health, Food Allergy Referral Centre Veneto Region, Padua General University Hospital, Padua, Italy
| | - Cezmi A Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland.,Servicio de Enfermedades del Sistema Inmune-Alergia, Departamento de Medicina y Especialidades Médicas, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | | | - M Beatrice Bilò
- Allergy Unit, Department of Internal Medicine, University Hospital of Ancona, Ancona, Italy
| | - Danijela Bokanovic
- Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria
| | - Moises A Calderon
- Section of Allergy and Clinical Immunology, Imperial College London, London, UK.,National Heart and Lung Institute, Royal Brompton Hospital, London, UK
| | - Ewa Cichocka-Jarosz
- Department of Pediatrics, Jagiellonian University Medical College, Kraków, Poland
| | - Joanna N G Oude Elberink
- Department of Allergology Internal Medicine, University Medical Hospital Groningen, University of Groningen, Groningen, The Netherlands
| | - Radoslaw Gawlik
- Department of Internal Medicine, Allergy and Clinical Immunology, Medical University of Silesia, Katowice, Poland
| | - Thilo Jakob
- Department of Dermatology and Allergology, University Medical Center Gießen and Marburg (UKGM), Justus Liebig University Gießen, Gießen, Germany
| | - Mitja Kosnik
- Medical Faculty Ljubljana, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia
| | - Joanna Lange
- Department of Pediatric Pneumonology and Allergy, Medical University of Warsaw, Warsaw, Poland
| | - Ervin Mingomataj
- Department of Allergollogy and Clinical Immunology, Mother Theresa School of Medicine, Tirana, Albania.,Department of Paraclinical Disciplines, Faculty of Technical-Medical Sciences, Medicine University of Tirana, Tirana, Albania
| | - Dimitris I Mitsias
- Department of Allergy and Clinical Immunology, 2nd Pediatric Clinic, University of Athens, Athens, Greece
| | - Holger Mosbech
- Allergy Clinic, Copenhagen University Hospital Gentofte, Gentofte, Denmark
| | - Oliver Pfaar
- Department of Otorhinolaryngology, Head and Neck Surgery, Center for Rhinology and Allergology, University Hospital, Mannheim, Wiesbaden, Germany
| | - Constantinos Pitsios
- Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.,Allergy Outpatient Clinic, Apollonio Hospital, Nicosia, Cyprus
| | - Valerio Pravettoni
- UOC Clinical Allergy and Immunology, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Graham Roberts
- NIHR Respiratory Biomedical Research Unit, The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport Isle of Wight, University Hospital Southampton NHS Foundation Trust, Southampton, UK.,Faculty of Medicine, University of Southampton, Southampton, UK
| | - Franziska Ruëff
- Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Munich, Germany
| | - Betül Ayşe Sin
- Division of Immunology and Allergy, Department of Pulmonary Diseases, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Aziz Sheikh
- Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK
| |
Collapse
|
4
|
Dhami S, Zaman H, Varga EM, Sturm GJ, Muraro A, Akdis CA, Antolín-Amérigo D, Bilò MB, Bokanovic D, Calderon MA, Cichocka-Jarosz E, Oude Elberink JNG, Gawlik R, Jakob T, Kosnik M, Lange J, Mingomataj E, Mitsias DI, Mosbech H, Ollert M, Pfaar O, Pitsios C, Pravettoni V, Roberts G, Ruëff F, Sin BA, Asaria M, Netuveli G, Sheikh A. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy 2017; 72:342-365. [PMID: 28120424 DOI: 10.1111/all.13077] [Citation(s) in RCA: 73] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/31/2016] [Indexed: 12/01/2022]
Abstract
BACKGROUND The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the management of insect venom allergy. To inform this process, we sought to assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy. METHODS We undertook a systematic review, which involved searching 15 international biomedical databases for published and unpublished evidence. Studies were independently screened and critically appraised using established instruments. Data were descriptively summarized and, where possible, meta-analysed. RESULTS Our searches identified a total of 16 950 potentially eligible studies; of which, 17 satisfied our inclusion criteria. The available evidence was limited both in volume and in quality, but suggested that venom immunotherapy (VIT) could substantially reduce the risk of subsequent severe systemic sting reactions (OR = 0.08, 95% CI 0.03-0.26); meta-analysis showed that it also improved disease-specific quality of life (risk difference = 1.41, 95% CI 1.04-1.79). Adverse effects were experienced in both the build-up and maintenance phases, but most were mild with no fatalities being reported. The very limited evidence found on modelling cost-effectiveness suggested that VIT was likely to be cost-effective in those at high risk of repeated systemic sting reactions and/or impaired quality of life. CONCLUSIONS The limited available evidence suggested that VIT is effective in reducing severe subsequent systemic sting reactions and in improving disease-specific quality of life. VIT proved to be safe and no fatalities were recorded in the studies included in this review. The cost-effectiveness of VIT needs to be established.
Collapse
Affiliation(s)
- S. Dhami
- Evidence-Based Health Care Ltd; Edinburgh UK
| | - H. Zaman
- School of Pharmacy; University of Bradford; Bradford UK
| | - E.-M. Varga
- Department of Pediatric and Adolescent Medicine; Respiratory and Allergic Disease Division; Medical University of Graz; Graz Austria
| | - G. J. Sturm
- Department of Dermatology and Venerology; Medical University of Graz; Graz Austria
- Outpatient Allergy Clinic Reumannplatz; Vienna Austria
| | - A. Muraro
- Department of Women and Child Health; Food Allergy Referral Centre Veneto Region; Padua General University Hospital; Padua Italy
| | - C. A. Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF); Switzerland Servicio de Enfermedades del Sistema Inmune-Alergia; University of Zurich; Zurich Switzerland
- Departamento de Medicina y Especialidades Médicas; Hospital Universitario Príncipe de Asturias; Madrid Spain
| | | | - M. B. Bilò
- Allergy Unit; Department of Internal Medicine; University Hospital of Ancona; Ancona Italy
| | - D. Bokanovic
- Department of Dermatology and Venerology; Medical University of Graz; Graz Austria
| | - M. A. Calderon
- Section of Allergy and Clinical Immunology; Imperial College London; National Heart and Lung Institute; Royal Brompton Hospital; London UK
| | - E. Cichocka-Jarosz
- Department of Pediatrics; Jagiellonian University Medical College; Krakow Poland
| | - J. N. G. Oude Elberink
- Department of Allergology and Internal Medicine; University of Groningen; University Medical Hospital Groningen; Groningen The Netherlands
- Groningen Research Center for Asthma and COPD (GRIAC); Groningen The Netherlands
| | - R. Gawlik
- Department of Internal Medicine, Allergy and Clinical Immunology; Medical University of Silesia; Katowice Poland
| | - T. Jakob
- Department of Dermatology and Allergology; University Medical Center Gießen and Marburg (UKGM); Justus Liebig University Gießen; Gießen Germany
| | - M. Kosnik
- Medical Faculty Ljubljana; University Clinic of Respiratory and Allergic Diseases Golnik; Golnik Slovenia
| | - J. Lange
- Department of Pediatric Pneumonology and Allergy; Medical University of Warsaw; Warsaw Poland
| | - E. Mingomataj
- Department of Allergology and Clinical Immunology; Mother Theresa School of Medicine; Tirana Albania
- Department of Paraclinical Disciplines; Faculty of Technical Medical Sciences; Medicine University of Tirana; Tirana Albania
| | - D. I. Mitsias
- Department of Allergy and Clinical Immunology; 2nd Pediatric Clinic; University of Athens; Athens Greece
| | - H. Mosbech
- Allergy Clinic; Copenhagen University Hospital Gentofte; Gentofte Denmark
| | - M. Ollert
- Department of Infection and Immunity; Luxembourg Institute of Health (LIH); Strassen Luxembourg
| | - O. Pfaar
- Department of Otorhinolaryngology; Head and Neck Surgery; Universitätsmedizin Mannheim; Mannheim Germany
- Medical Faculty Mannheim; Heidelberg University; Heidelberg Germany
- Center for Rhinology Allergology; Wiesbaden Germany
| | - C. Pitsios
- Medical School; University of Cyprus; Nicosia Cyprus
| | - V. Pravettoni
- UOC Clinical Allergy and Immunology; IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico; Milan Italy
| | - G. Roberts
- The David Hide Asthma and Allergy Research Centre; St Mary's Hospital; Newport Isle of Wight UK
- NIHR Respiratory Biomedical Research Unit; University Hospital Southampton NHS Foundation Trust; Southampton UK
- Faculty of Medicine; University of Southampton; Southampton UK
| | - F. Ruëff
- Klinik und Poliklinik für Dermatologie und Allergologie; Klinikum der Universität München; Munich Germany
| | - B. A. Sin
- Department of Pulmonary Diseases; Division of Immunology and Allergy; Faculty of Medicine; Ankara University; Ankara Turkey
| | - M. Asaria
- Research Fellow Centre for Health Economics; University of York; UK
| | - G. Netuveli
- Institute for Health and Human Development; University of East London; London UK
| | - A. Sheikh
- Allergy and Respiratory Research Group; The University of Edinburgh; Edinburgh UK
| |
Collapse
|
5
|
Dhami S, Nurmatov U, Varga EM, Sturm G, Muraro A, Akdis CA, Antolín-Amérigo D, Bilò MB, Bokanovic D, Calderon MA, Cichocka-Jarosz E, Elberink JNGO, Gawlik R, Jakob T, Kosnik M, Lange J, Mingomataj E, Mitsias DI, Mosbech H, Pfaar O, Pitsios C, Pravettoni V, Roberts G, Ruëff F, Sin BA, Sheikh A. Allergen immunotherapy for insect venom allergy: protocol for a systematic review. Clin Transl Allergy 2016; 6:6. [PMID: 26885362 PMCID: PMC4754882 DOI: 10.1186/s13601-016-0095-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Accepted: 01/11/2016] [Indexed: 12/02/2022] Open
Abstract
Background
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Insect Venom Allergy. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy.
Methods We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised.
Discussion
The findings from this review will be used to inform the development of recomendations for EAACI’s Guidelines on AIT.
Collapse
Affiliation(s)
| | - Ulugbek Nurmatov
- Systematic Review at Decision Resources Group, Abacus International, Bicester, UK
| | - Eva-Maria Varga
- Respiratory and Allergic Disease Division, Department of Pediatric and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - Gunter Sturm
- Department of Dermatology and Venerology, Medical University of Graz and Outpatient Allergy Clinic Reumannplatz, Vienna, Austria
| | - Antonella Muraro
- Department of Women and Child Health, Food Allergy Referral Centre Veneto Region, Padua General University Hospital, Padua, Italy
| | - Cezmi A Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland ; Servicio de Enfermedades del Sistema Inmune-Alergia, Departamento de Medicina y Especialidades Médicas, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | | | - M Beatrice Bilò
- Allergy Unit, Department of Internal Medicine, University Hospital of Ancona, Ancona, Italy
| | - Danijela Bokanovic
- Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria
| | - Moises A Calderon
- Section of Allergy and Clinical Immunology, Imperial College London, London, UK ; National Heart and Lung Institute, Royal Brompton Hospital, London, UK
| | - Ewa Cichocka-Jarosz
- Department of Pediatrics, Jagiellonian University Medical College, Kraków, Poland
| | - Joanna N G Oude Elberink
- Department of Allergology Internal Medicine, University Medical Hospital Groningen, University of Groningen, Groningen, The Netherlands
| | - Radoslaw Gawlik
- Department of Internal Medicine, Allergy and Clinical Immunology, Medical University of Silesia, Katowice, Poland
| | - Thilo Jakob
- Department of Dermatology and Allergology, University Medical Center Gießen and Marburg (UKGM), Justus Liebig University Gießen, Gießen, Germany
| | - Mitja Kosnik
- Medical Faculty Ljubljana, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia
| | - Joanna Lange
- Department of Pediatric Pneumonology and Allergy, Medical University of Warsaw, Warsaw, Poland
| | - Ervin Mingomataj
- Department of Allergollogy and Clinical Immunology, Mother Theresa School of Medicine, Tirana, Albania ; Department of Paraclinical Disciplines, Faculty of Technical-Medical Sciences, Medicine University of Tirana, Tirana, Albania
| | - Dimitris I Mitsias
- Department of Allergy and Clinical Immunology, 2nd Pediatric Clinic, University of Athens, Athens, Greece
| | - Holger Mosbech
- Allergy Clinic, Copenhagen University Hospital Gentofte, Gentofte, Denmark
| | - Oliver Pfaar
- Department of Otorhinolaryngology, Head and Neck Surgery, Center for Rhinology and Allergology, University Hospital, Mannheim, Wiesbaden, Germany
| | - Constantinos Pitsios
- Department of Nutrition and Dietetics, Harokopio University, Athens, Greece ; Allergy Outpatient Clinic, Apollonio Hospital, Nicosia, Cyprus
| | - Valerio Pravettoni
- UOC Clinical Allergy and Immunology, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Graham Roberts
- NIHR Respiratory Biomedical Research Unit, The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport Isle of Wight, University Hospital Southampton NHS Foundation Trust, Southampton, UK ; Faculty of Medicine, University of Southampton, Southampton, UK
| | - Franziska Ruëff
- Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Munich, Germany
| | - Betül Ayşe Sin
- Division of Immunology and Allergy, Department of Pulmonary Diseases, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Aziz Sheikh
- Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, UK
| |
Collapse
|
6
|
Ibranji A, Nikolla E, Loloci G, Mingomataj E. A case report on transitory histamine intolerance from strawberry intake in a 15 month old child with acute gastroenteritis. Clin Transl Allergy 2015. [PMCID: PMC4412621 DOI: 10.1186/2045-7022-5-s3-p61] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
7
|
Mingomataj E, Dinh QT, Groneberg D, Feleszko W, Schmeck B, Joachim R, Noga O, Nagel S, Klapp BF, Fischer A. Trigeminal nasal-specific neurons respond to nerve growth factor with substance-P biosynthesis. Clin Exp Allergy 2008; 38:1203-11. [PMID: 18307524 DOI: 10.1111/j.1365-2222.2008.02957.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Nerve growth factor (NGF) has been found to induce substance-P biosynthesis in large-diameter A-fibres vagal airway neurons. However, the effect of NGF on trigeminal neurons innervating the nasal mucosa of the mouse has not been investigated so far. OBJECTIVE NGF has been implicated in allergic diseases by modulating sensory nerves. Therefore, the present study investigated the effect of NGF on neuropeptides expression such as substance-P and glutamate in nasal trigeminal neurons. METHODS Using neuronal tracing in combination with double labelling immunohistochemistry the expression of substance-P, glutamate and neurofilament protein 68-kDa expression was examined in nasal-specific trigeminal neurons of BALB/c-mice. RESULTS The numbers of Fast blue-labelled trigeminal neurons expressing substance-P were significantly increased after NGF exposure (NGF-treated ganglia: 16.4 +/- 0.6% vs. control: 7.0 +/- 0.4%, P<or=0.001). NGF treatment-induced substance-P biosynthesis in neurofilament-positive (NGF-treated ganglia: 8.6 +/- 0.2% vs. control: 1.1 +/- 0.2%, P<or=0.001) as well as neurofilament-negative (NGF-treated ganglia: 7.8 +/- 0.6% vs. control: 5.9 +/- 0.4%, P=0.05) and non-glutamatergic neurons (NGF-treated ganglia: 11.8 +/- 1.9% vs. control 1.1 +/- 1.0%, P<or=0.001) 24 h after NGF exposure. CONCLUSION Under normal conditions, substance-P was expressed in nasal-specific neurofilament-negative, glutamatergic and C-fibre neurons. Nasal-specific trigeminal neurons respond to NGF treatment with substance-P biosynthesis in non-glutamatergic, neurofilament-positive as well as -negative neurons. These findings suggest that nasal-specific trigeminal neurons are composed of heterogenous subpopulations in relation to their peptide profiles and therefore may have different functions in neurogenic airway inflammation.
Collapse
Affiliation(s)
- E Mingomataj
- Department of Pneumology and Immunology, Allergy-Centre-Charité, Otto-Heubner-Centre, Clinical Research Unit of Allergy, Berlin, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Dinh QT, Mingomataj E, Quarcoo D, Groneberg DA, Witt C, Klapp BF, Braun A, Fischer A. Allergic airway inflammation induces tachykinin peptides expression in vagal sensory neurons innervating mouse airways. Clin Exp Allergy 2006; 35:820-5. [PMID: 15969675 DOI: 10.1111/j.1365-2222.2005.02264.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Allergic airway inflammation has been shown to induce pro-inflammatory neuropeptides such as tachykinin peptides substance P (SP) and neurokinin A (NKA) together with related peptide like calcitonin gene-related peptide (CGRP) in nodose sensory neurons innervating guinea-pig airways. OBJECTIVE The present study was designed to examine the effects of allergen sensitization and challenge on the SP/NKA expression in the jugular-nodose ganglion neurons innervating the murine airways. METHODS Using retrograde neuronal tracing technique in combination with double-labelling immunohistochemistry, the expression of SP/NKA was investigated in a murine model of allergic airway inflammation. RESULTS Allergic airway inflammation was found to induce the expression of SP/NKA (13.2+/-1.43% vs. 5.8+/-0.37%, P<0.01) in large-diameter (>20 microm) vagal sensory neurons retrograde labelled with Fast blue dye from the main stem bronchi. CONCLUSION Based on the induction of tachykinins in airway-specific large-sized jugular-nodose ganglia neurons by allergic airway inflammation, the present study suggests that allergen sensitization and challenge may lead to de novo induction of tachykinins in neurons. This may partly contribute to the pathogenesis of airways diseases such as allergic airway inflammation.
Collapse
Affiliation(s)
- Q T Dinh
- Department of Internal Medicine, Charité School of Medicine, Humboldt and Freie University Berlin, Berlin, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Dinh QT, Mingomataj E, Quarcoo D, Groneberg DA, Peiser C, Klapp BF, Braun A, Fischer A. Die Bedeutung von Pan-Neurotrophin Rezeptor p75 an der Substanz P-Induktion in vagal sensiblen Neurone der Atemswege der Maus. Pneumologie 2005. [DOI: 10.1055/s-2005-864477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
10
|
Dinh QT, Groneberg DA, Peiser C, Mingomataj E, Joachim RA, Witt C, Arck PC, Klapp BF, Fischer A. Substance P expression in TRPV1 and trkA-positive dorsal root ganglion neurons innervating the mouse lung. Respir Physiol Neurobiol 2005; 144:15-24. [PMID: 15522699 DOI: 10.1016/j.resp.2004.08.001] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/03/2004] [Indexed: 11/17/2022]
Abstract
In the present study, the co-localisation of substance P (SP) with the vanilloid receptor TRPV1 and the neurotrophin receptor tyrosine kinase trkA was analysed in airway-specific murine dorsal root ganglion (DRG) neurons. DRG neurons labelled with Fast Blue were predominantly found at the segmental levels T2-T5. Immunoreactivity for the receptor TRPV1 was localized to 12% of Fast Blue labelled DRG neurons. Double-labelling immunohistochemistry revealed that a substantial number of them also co-express SP (7.6 +/- 1.1% (mean +/- S.E.M.)), whereas neurons with immunoreactivity for TRPV1 only were found in 4.4 +/- 1.3% of the retrogradely labelled neuronal population. Further analysis of retrogradely labelled neurons showed that their majority expressed trkA (62.8 +/- 1.4%), neurofilament protein 68-kDa (64.8 +/- 1.5%) or glutamate alone (19.5 +/- 1.9%). SP was always expressed in trkA-positive neurons. Based on the extent of co-localization of SP with the receptors TRPV1 and trkA in DRG airway neurons, the present study indicates that the DRG pathway may have effects on the magnitude of neurogenic inflammation in airway diseases such as asthma.
Collapse
Affiliation(s)
- Q Thai Dinh
- Department of Medicine, Charité, School of Medicine, Humboldt University, Ostring 3, R. 3.0066, Augustenburger Platz 1, Berlin D-13353, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Mingomataj E, Ohri D, Dhimitri V, Priftanji A, Qirko E, Pani L, Fischer TC, Dinh QT, Peiser C, Fischer A, Groneberg DA. Hymenoptera sting anaphylactic reactions in the Mediterranean population of Albania. J Investig Allergol Clin Immunol 2003; 13:272-7. [PMID: 14989117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND Relatively few studies have examined the relation of different hymenoptera sting reactions. OBJECTIVE To investigate the relation of anaphylactic reactions against stings of different hymenoptera subspecies in the Mediterranean population of Albania. MATERIALS AND METHODS A retrospective study was conducted using the clinic files of 111 patients who were diagnosed for hymenoptera sting reactions from 1987 to 1996. Antigens used consisted of purified hymenoptera venom (bee, wasp, and paperwasp). The patients were diagnosed by intracutaneous tests in concentrations of 0.001 microgram/ml, 0.01 microgram/ml, 0.1 microgram/ml, and 1 microgram/ml. RESULTS The median age of the patients was 27 years. 57% of stings occurred between 20 to 40 years of age. The majority of anaphylactic reactions were recorded during the months of June to October, 81% of the patients were admitted to the hospital due to Mueller grade II to III reactions. In 26% of all cases, crossreactions (bee-wasp 16%, bee-wasp-paperwasp 7%, wasp-paperwasp 2%, bee-paperwasp 1%) were found. Of all anaphylactic reactions, 64% were attributed to bees, 24% to wasps, 8% to both bees and wasps, and 2% to paperwasps. CONCLUSIONS In contrast to industrialized countries such as the United States or Western Europe where urban populations predominate, reactions to bee venom were more prevalent in the present study population.
Collapse
Affiliation(s)
- E Mingomataj
- Dept. of Allergology, Mother Theresa School of Medicine, University of Tirana, Tirana, Albania.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Mingomataj E, Priftanji A, Qirko E, Dinh QT, Fischer A, Peiser C, Groneberg DA. Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms. BMC Dermatol 2002; 2:11. [PMID: 12201901 PMCID: PMC128821 DOI: 10.1186/1471-5945-2-11] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/25/2002] [Accepted: 08/30/2002] [Indexed: 11/10/2022]
Abstract
BACKGROUND Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards hymenoptera venom in the mediterranean population of Albania. METHODS A retrospective study was performed using the clinical reports of 37 patients with venom of bee (apinae), wasp (vespidae, subfamily vespinae) or paperwasp (vespidae, subfamily polistinae) allergy treated with Rush-SIT between 1987 and 1996. After hymenoptera sting allergy diagnosis according to anamnesis and intracutaneous tests the patient were treated with Rush-SIT. The protocol lasted 3 - 4 d with an increase in the concentration from 0.01 microg/ml to 100 microg/ml. Anaphylactic reactions were classified according to the Mueller-classification. RESULTS The frequency of reactions during Rush-SIT for bee-venom was 4.7% and for wasp-venom was 1.5% (p < 0.01). The mean frequency of reactions of Mueller grade II for the bee-venom Rush-SIT patients during the first 4 d (= 26 injections) was 0.73 and for the wasp-venom Rush-SIT patients 0.15. No patient experienced a third-degree reaction. 94.6% of the patient supported an end dose of 100 microg. CONCLUSIONS Rush-SIT is a reliable method for the treatment of anaphylactic reactions to hymenoptera venom even in less developed countries. Bee-venom Rush-SIT was found to cause higher numbers allergic reactions than wasp or paperwasp Rush-SIT.
Collapse
Affiliation(s)
- Ervin Mingomataj
- Dept. of Allergy, Mother Theresa School of Medicine, University of Tirana, Tirana, Albania
- Division of Allergy Research, Dept. of Pediatric Pneumology and Immunology, Charité School of Medicine, Humboldt-University, D-13353 Berlin, Germany
| | - Alfred Priftanji
- Dept. of Allergy, Mother Theresa School of Medicine, University of Tirana, Tirana, Albania
| | - Etleva Qirko
- Dept. of Allergy, Mother Theresa School of Medicine, University of Tirana, Tirana, Albania
| | - Q Thai Dinh
- Division of Allergy Research, Dept. of Pediatric Pneumology and Immunology, Charité School of Medicine, Humboldt-University, D-13353 Berlin, Germany
| | - Axel Fischer
- Division of Allergy Research, Dept. of Pediatric Pneumology and Immunology, Charité School of Medicine, Humboldt-University, D-13353 Berlin, Germany
| | - Christian Peiser
- Division of Allergy Research, Dept. of Pediatric Pneumology and Immunology, Charité School of Medicine, Humboldt-University, D-13353 Berlin, Germany
| | - David A Groneberg
- Division of Allergy Research, Dept. of Pediatric Pneumology and Immunology, Charité School of Medicine, Humboldt-University, D-13353 Berlin, Germany
| |
Collapse
|